Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination.

Samadi-Foroushani M, Vahabpour R, Memarnejadian A, Namdar A, Khamisabadi M, Sadat SM, Asgarian-Omran H, Azadmanesh K, Kokhaei P, Aghasadeghi MR, Hadjati J.

Med Oncol. 2011 Dec;28 Suppl 1:S660-6. doi: 10.1007/s12032-010-9720-z. Epub 2010 Nov 2.

PMID:
21042958
2.

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.

Conroy H, Galvin KC, Higgins SC, Mills KH.

Cancer Immunol Immunother. 2012 Mar;61(3):425-31. doi: 10.1007/s00262-011-1188-y. Epub 2011 Dec 23.

PMID:
22193988
3.

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW.

Neuro Oncol. 2009 Oct;11(5):529-42. doi: 10.1215/15228517-2009-004. Epub 2009 Mar 31.

4.

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.

Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama D, Becker JC.

Cancer Immunol Immunother. 2007 Jul;56(7):1017-24. Epub 2006 Dec 29.

PMID:
17195079
5.

The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH.

J Immunother. 2009 Jan;32(1):22-8. doi: 10.1097/CJI.0b013e31818ac2f7.

PMID:
19307990
6.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
7.

Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Woller N, Knocke S, Mundt B, Gürlevik E, Strüver N, Kloos A, Boozari B, Schache P, Manns MP, Malek NP, Sparwasser T, Zender L, Wirth TC, Kubicka S, Kühnel F.

J Clin Invest. 2011 Jul;121(7):2570-82. doi: 10.1172/JCI45585. Epub 2011 Jun 6.

8.

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.

Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX.

Cancer Immunol Immunother. 2007 Oct;56(10):1597-604. Epub 2007 Apr 18.

PMID:
17440723
9.

Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.

Yan X, Zhang X, Wang Y, Li X, Wang S, Zhao B, Li Y, Ju Y, Chen L, Liu W, Meng S.

Cancer Immunol Immunother. 2011 Dec;60(12):1763-74. doi: 10.1007/s00262-011-1076-5. Epub 2011 Jul 26.

PMID:
21789592
10.

A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD.

Clin Cancer Res. 2009 Jan 15;15(2):641-9. doi: 10.1158/1078-0432.CCR-08-1988.

11.

Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.

Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y.

Oncol Rep. 2009 Aug;22(2):337-43.

PMID:
19578774
12.

Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.

Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E.

Cancer Res. 2007 Jan 1;67(1):371-80.

13.
15.

Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.

Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG.

Vaccine. 2010 Nov 16;28(49):7787-96. doi: 10.1016/j.vaccine.2010.09.046. Epub 2010 Sep 28.

PMID:
20883737
16.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

17.
18.

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.

J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8.

PMID:
21150709
19.

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.

Driessens G, Gordower L, Nuttin L, Stordeur P, Blocklet D, Egrise D, Velu T, Bruyns C.

Cancer Immunol Immunother. 2008 Dec;57(12):1745-56. doi: 10.1007/s00262-008-0500-y. Epub 2008 Mar 28.

PMID:
18369621
20.

Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.

Khamisabadi M, Arab S, Motamedi M, Khansari N, Moazzeni SM, Gheflati Z, Hadjati J.

Iran J Immunol. 2008 Mar;5(1):36-44. doi: IJIv5i1A3.

PMID:
18319523

Supplemental Content

Support Center